Ausgewählte Publikationen
- Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
Schwichtenberg SC, Wisgalla A, Schroeder-Castagno M, Alvarez-González C, Schlickeiser S, Siebert N, Bellmann-Strobl J, Wernecke KD, Paul F, Dörr J, Infante-Duarte C.Neurotherapeutics. 2021 Jul;18(3):1783-1797. doi: 10.1007/s13311-021-01078-7. Epub 2021 Jul 9.PMID: 34244929 - Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.
Brandt AU, Sy M, Bellmann-Strobl J, Newton BL, Pawling J, Zimmermann HG, Yu Z, Chien C, Dörr J, Wuerfel JT, Dennis JW, Paul F, Demetriou M.JAMA Neurol. 2021 Jul 1;78(7):842-852. doi: 10.1001/jamaneurol.2021.1116.PMID: 33970182 - Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial.
Bellmann-Strobl J, Paul F, Wuerfel J, Dörr J, Infante-Duarte C, Heidrich E, Körtgen B, Brandt A, Pfüller C, Radbruch H, Rust R, Siffrin V, Aktas O, Heesen C, Faiss J, Hoffmann F, Lorenz M, Zimmermann B, Groppa S, Wernecke KD, Zipp F.Neurol Neuroimmunol Neuroinflamm. 2021 Mar 24;8(3):e981. doi: 10.1212/NXI.0000000000000981. Print 2021 May.PMID: 33762428 - Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.
Rust R, Chien C, Scheel M, Brandt AU, Dörr J, Wuerfel J, Klumbies K, Zimmermann H, Lorenz M, Wernecke KD, Bellmann-Strobl J, Paul F.Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(3):e964. doi: 10.1212/NXI.0000000000000964. Print 2021 May.PMID: 33622766 - High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial.
Dörr J, Bäcker-Koduah P, Wernecke KD, Becker E, Hoffmann F, Faiss J, Brockmeier B, Hoffmann O, Anvari K, Wuerfel J, Piper SK, Bellmann-Strobl J, Brandt AU, Paul F.Mult Scler J Exp Transl Clin. 2020 Jan 24;6(1):2055217320903474. doi: 10.1177/2055217320903474. eCollection 2020 Jan-Mar.PMID: 32047645 - Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.
Dörr J, Wernecke KD, Würfel J, Bellmann-Strobl J, Siffrin V, Sättler MB, Simons M, Linsa A, Tumani H, Paul F.Front Neurol. 2018 Oct 9;9:842. doi: 10.3389/fneur.2018.00842. eCollection 2018.PMID: 30356868 - A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
Stürner KH, Stellmann JP, Dörr J, Paul F, Friede T, Schammler S, Reinhardt S, Gellissen S, Weissflog G, Faizy TD, Werz O, Fleischer S, Vaas LAI, Herrmann F, Pless O, Martin R, Heesen C.J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):330-338. doi: 10.1136/jnnp-2017-317101. Epub 2017 Dec 16.PMID: 29248894 Clinical Trial. - Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.
Koduah P, Paul F, Dörr JM.EPMA J. 2017 Nov 15;8(4):313-325. doi: 10.1007/s13167-017-0120-8. eCollection 2017 Dec.PMID: 29209434 - Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
Dörr J, Baum K.Drug Des Devel Ther. 2016 Oct 18;10:3379-3386. doi: 10.2147/DDDT.S97956. eCollection 2016.PMID: 27799738 - Haemopoietic stem-cell transplantation for multiple sclerosis: what next?
Dörr J.Lancet. 2016 Aug 6;388(10044):536-8. doi: 10.1016/S0140-6736(16)30377-4. Epub 2016 Jun 9.PMID: 27291993 No abstract available. - Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis.
Behrens JR, Rasche L, Gieß RM, Pfuhl C, Wakonig K, Freitag E, Deuschle K, Bellmann-Strobl J, Paul F, Ruprecht K, Dörr J.Eur J Neurol. 2016 Jan;23(1):62-7. doi: 10.1111/ene.12788. Epub 2015 Jul 28.PMID: 26220765 - The transition from first-line to second-line therapy in multiple sclerosis.
Dörr J, Paul F.Curr Treat Options Neurol. 2015 Jun;17(6):354. doi: 10.1007/s11940-015-0354-5.PMID: 25912246 - Optical coherence tomography for retinal imaging in multiple sclerosis.
Zimmermann H, Oberwahrenbrock T, Brandt AU, Paul F, Dörr J.Degener Neurol Neuromuscul Dis. 2014 Dec 9;4:153-162. doi: 10.2147/DNND.S73506. eCollection 2014.PMID: 32669908 - Optimal management of multiple sclerosis during pregnancy: current perspectives.
Borisow N, Paul F, Dörr J.Degener Neurol Neuromuscul Dis. 2014 Aug 5;4:111-120. doi: 10.2147/DNND.S48618. eCollection 2014.PMID: 32669905
